Mr. DeLuccia is a co-founder of Acurx Pharmaceuticals and has served as its Executive Chairman and as a director since February 2018. Previously he was Executive Chairman of Dipexium Pharmaceuticals (Nasdaq: DPRX) from February 2010 until its April 2017 sale to PLx Pharma Inc. From 2004 to 2009 he held several roles at MacroChem, including Chairman, President and Chief Executive Officer, and earlier served as President and Chief Executive Officer of Immunomedics, Inc. and as President of Sterling Winthrop, Inc. (later the U.S. subsidiary of Sanofi-Aventis). He served on the board of IBEX Technologies Inc. until its 2024 sale to BBI Solutions. Mr. DeLuccia began his career as a pharmaceutical sales representative at Pfizer, rising to Vice President of Marketing and Sales Operations for Pfizer's Roerig Division. He holds a B.B.A. in Marketing and an M.B.A. from Iona College.